The molecular biology of chronic wounds and delayed healing in diabetes

Diabetic Medicine

Volumn 23, Issue 6, 2006, Pages 594-608

  Blakytny, R ^a   Jude, E ^b  

^a Fachklinik Hornheide   (Germany)

^b TAMESIDE GENERAL HOSPITAL   (United Kingdom)

Author keywords

Chronic wounds; Growth factors; Matrix metalloproteinases; Nitric oxide; Wound healing

Indexed keywords

GLUCOSE; GROWTH FACTOR; MATRIX METALLOPROTEINASE; NERVE GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; SOMATOMEDIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANGIOGENESIS; CHRONIC WOUND; COST CONTROL; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE MODEL; DNA DAMAGE; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; GLYCATION; HUMAN; MOLECULAR BIOLOGY; NEUTROPHIL; OXIDATION REDUCTION REACTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUALITY OF LIFE; REVIEW; SKIN ULCER; TREATMENT PLANNING; WOUND HEALING IMPAIRMENT;

ANIMALS; CYTOKINES; DIABETES COMPLICATIONS; DIABETES MELLITUS, EXPERIMENTAL; EXTRACELLULAR MATRIX; GLUCOSE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NITRIC OXIDE; OXIDATION-REDUCTION; SKIN; WOUND HEALING;

EID: 33744780764     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2006.01773.x     Document Type: Review

References (221)

1. Singer AJ Clark RAF. Cutaneous wound healing. N Engl J Med 1999 341 : 738 746.
2. Chettibi S Ferguson MWJ. Wound repair: an overview. In : Gallin JI Snyderman R, eds. Inflammation: Basic Principles and Clinical Correlates, 3rd edn. Philadelphia : Lippincott. Williams and Wilkins 1999 : 865 881.
3. Brunner G Blakytny R. Extracellular regulation of TGF-β activity in wound repair: growth factor latency as a sensor mechanism for injury. Thromb Haemost 2004 92 : 253 261.
4. Koivukangas V Annala AP Salmela PI Oikarinen A. Delayed restoration of epidermal barrier function after suction blister injury in patients with diabetes mellitus. Diabet Med 1999 16 : 563 567.
5. Jude EB Boulton AJM. End-stage complications of diabetic neuropathy. Diabet Rev 1999 7 : 395 410.
6. Jeffcoate WJ Harding KG. Diabetic foot ulcers. Lancet 2003 361 : 1545 1551.
7. Ramsey SD Newton K Blough D McCulloch DK Sandhu N Reiber GE et al. Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabetes Care 1999 22 : 382 387.
8. Adler AI Boyko EJ Ahroni JH Smith DG. Lower-extremity amputation in diabetes. The independent effects of peripheral vascular disease, sensory neuropathy, and foot ulcers. Diabetes Care 1999 22 : 1029 1035.
9. Ferguson MW Herrick SE Spencer MJ Shaw JE Boulton AJ Sloan P. The histology of diabetic foot ulcers. Diabet Med 1996 13 : S30 33.
10. Delamaire M Maugendre D Moreno M Le Goff MC Allannic H Genetet B. Impaired leucocyte functions in diabetic patients. Diabet Med 1997 14 : 29 34.
11. Wysocki J Wierusz-Wysocka B Wykretowicz A Wysocki H. The influence of thymus extracts on the chemotaxis of polymorphonuclear neutrophils (PMN) from patients with insulin-dependent diabetes mellitus (IDD). Thymus 1992 20 : 63 67.
12. Jeffcoate WJ Price P Harding KG. Wound healing and treatments for people with diabetic foot ulcers. Diabetes Metab Res Rev 2004 20 : S78 S89.
13. Ehrlichman RJ Seckel BR Bryan DJ Moschella CJ. Common complications of wound healing. Prevention and management. Surg Clin North Am 1991 71 : 1323 1351.
14. Greenhalgh DG. The role of growth factors in wound healing. J Trauma 1996 41 : 159 167.
15. Grant M Jerdan J Merimee TJ. Insulin-like growth factor-1 modulates endothelial cell chemotaxis. J Clin Endocrinol Metab 1987 65 : 370 371.
16. Kratz G Lake M Ljungstrom K Forsberg G Haegerstand A Gidlund M. Effect of recombinant IGF binding protein-1 on primary cultures of human keratinocytes and fibroblasts: selective enhancement of IGF-1 but not IGF-2 induced cell profileration. Exp Cell Res 1992 202 : 381 385.
17. Bhora FY Dunkin BJ Batzri S Aly HM Bass BL Sidawy AN et al. Effect of growth factors on cell proliferation and epithelialization in human skin. J Surg Res 1995 59 : 236 244.
18. Tsuboi R Shi CM Sato C Cox GN Ogawa H. Co-administration of insulin-like growth factor (IGF) -I and IGF-binding protein-1 stimulates wound healing in animal models. J Invest Dermatol 1995 104 : 199 203.
19. Bitar MS. Insulin-like growth factor-1 reverses diabetes-induced wound healing impairment in rats. Horm Metab Res 1997 29 : 383 386.
20. Brown DL Kane CD Chernausek SD Greenhalgh DG. Differential expression and localization of insulin-like growth factors I and II in cutaneous wounds of diabetic and non-diabetic mice. Am J Pathol 1997 151 : 715 724.
21. Bitar MS. Insulin and glucocorticoid-dependent suppression of the IGF-I system in diabetic wounds. Surgery 2000 127 : 687 695.
22. Bitar MS Labbad ZN. Transforming growth factor-β and insulin-like growth factor I in relation to diabetes-induced impairment of wound healing. J Surg Res 1996 61 : 113 119.
23. Blakytny R Jude EB Gibson JM Boulton AJM Ferguson MWJ. Lack of insulin-like growth factor I (IGF I) in the basal keratinocyte layer of diabetic skin and diabetic foot ulcers. J Pathol 2000 190 : 589 594.
24. Dennis PA Rifkin DB. Cellular activation of latent transforming growth factor β requires binding to the cation-independent mannose 6 -phosphate/insulin-like growth factor type II receptor. Proc Natl Acad Sci USA 1991 88 : 580 584.
25. Kane CJ Hebda PA Mansbridge JN Hanawalt PC. Direct evidence for spatial and temporal regulation of transforming growth factor β1 expression during cutaneous wound healing. J Cell Physiol 1991 148 : 157 173.
26. Levine JH Moses HL Gold LI Nanney LB. Spatial and temporal patterns of immunoreactive transforming growth factor β1, β2, and β3 during excisional wound repair. Am J Pathol 1993 143 : 368 380.
27. Roberts AB. Transforming growth factor-β: activity and efficacy in animal models of wound healing. Wound Rep Regen 1995 3 : 408 418.
28. Frank S Madlener M Werner S. Transforming growth factors β1, β2, and β3 and their receptors are differentially regulated during normal and impaired wound healing. J Biol Chem 1996 271 : 10188 10193.
29. O'Kane S Ferguson MWJ. Transforming growth factor βs and wound healing. Int J Biochem Cell Biol 1997 29 : 63 78.
30. Jude EB Blakytny R Bulmer J Boulton AJ Ferguson MW. Transforming growth factor-β1, -2, -3 and receptor type I and II in diabetic foot ulcers. Diabet Med 2002 19 : 440 447.
31. Bennett NT Schultz GS. Growth factors and wound healing: biochemical properties of growth factors and their receptors. Am J Surg 1993 165 : 728 737.
32. Steed DL. The role of growth factors in wound healing. Surg Clin North Am 1997 77 : 575 586.
33. Schmid P Cox D Bilbe G McMaster G Morrison C Stahelin H et al. TGF-βs and TGF-β Type II receptor in human epidermis: differential expression in acute and chronic skin wounds. J Pathol 1993 171 : 191 197.
34. Jude EB Boulton AJM Ferguson MWJ Appleton I. The role of nitric oxide synthase isoforms and arginase in the pathogenesis of diabetic foot ulcers: possible modulatory effects by transforming growth factor β1. Diabetologia 1999 42 : 748 757.
35. Derynck R Feng XH. TGF-β receptor signaling. Biochim Biophys Acta 1997 1333 : F105 F150.
36. Schmid P Itin P Cherry G Bi C Cox DA. Enhanced expression of transforming growth factor-β type I and type II receptors in wound granulation tissue and hypertrophic scar. Am J Pathol 1998 152 : 485 493.
37. Shah M Foreman DM Ferguson MW. Neutralisation of TGF-β1 and TGF-β2 or exogenous addition of TGF-β3 to cutaneous rat wounds reduces scarring. J Cell Sci 1995 108 : 985 1002.
38. Kahn RC Smith RJ Shin WW. Mechanism of action of hormones that act at the cell surface. In : Wilson JD Foster DW, eds. Williams Textbook of Endocrinology, 8th edn. Philadelphia : W.B. Saunders and Co. 1992 : 91 134.
39. Heldin CH Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999 79 : 1283 1316.
40. Goldman R. Growth factors and chronic wound healing: past, present, and future. Adv Skin Wound Care 2004 17 : 24 35.
41. Castronuovo JJ Ghobrial I Giusti AM Rudolph S Smiell JM. Effects of chronic wound fluid on the structure and biological activity of becaplermin (rhPDGF-BB) and becaplermin gel. Am J Surg 1998 176 : 61S 67S.
42. Doxey DL Ng MC Dill RE Iacopino AM. Platelet-derived growth factor levels in wounds of diabetic rats. Life Sci 1995 57 : 1111 1123.
43. Beer HD Longaker MT Werner S. Reduced expression of PDGF and PDGF receptors during impaired wound healing. J Invest Dermatol 1997 109 : 132 138.
44. Soma Y Grotendorst GR. TGF-β stimulates primary human skin fibroblast DNA synthesis via an autocrine production of PDGF-related peptides. J Cell Physiol 1989 140 : 246 253.
45. Pierce GF Mustoe TA Lingelbach J Masakowski VR Griffin GL Senior RM et al. Platelet-derived growth factor and transforming growth factor-β enhance tissue repair activities by unique mechanisms. J Cell Biol 1989 109 : 429 440.
46. Bonini S Rasi G Bracci-Laudiero ML Procoli A Aloe L. Nerve growth factor: neurotrophin or cytokine? Int Arch Allergy Immunol 2003 131 : 80 84.
47. Graiani G Emanueli C Desortes E Van Linthout S Pinna A Figueroa CD et al. Nerve growth factor promotes reparative angiogenesis and inhibits endothelial apoptosis in cutaneous wounds of type 1 diabetic mice. Diabetologia 2004 47 : 1047 1054.
48. Matsuda H Kannan Y Ushio H Kiso Y Kanemoto T Suzuki H et al. Nerve growth factor induces development of connective tissue-type mast cells in vitro from murine bone marrow cells. J Exp Med 1991 174 : 7 14.
49. Cantarella G Lempereur L Presta M Ribatti D Lombardo G Lazarovici P et al. Nerve growth factor-endothelial cell interaction leads to angiogenesis in vitro and in vivo. FASEB J 2002 16 : 1307 1309.
50. Di Marco E Marchisio PC Bondanza S Franzi AT Cancedda R De Luca M. Growth-regulated synthesis and secretion of biologically active nerve growth factor by human keratinocytes. J Biol Chem 1991 266 : 21718 21722.
51. Di Marco E Mathor M Bondanza S Cutuli N Marchisio PC Cancedda R et al. Nerve growth factor binds to normal human keratinocytes through high- and low-affinity receptors and stimulates their growth by a novel autocrine loop. J Biol Chem 1993 268 : 22838 22846.
52. Ehrhard PB Ganter U Bauer J Otten U. Expression of functional trk protooncogene in human monocytes. Proc Natl Acad Sci USA 1993 90 : 5423 5427.
53. Kannan Y Ushio H Koyama H Okada M Oikawa M Yoshihara T et al. 2.5S nerve growth factor enhances survival, phagocytosis, and superoxide production of murine neutrophils. Blood 1991 77 : 1320 1325.
54. Fernyhough P Diemel LT Hardy J Brewster WJ Mohiuddin L Tomlinson DR. Human recombinant nerve growth factor replaces deficient neurotrophic support in the diabetic rat. Eur J Neurosci 1995 7 : 1107 1110.
55. Riaz S Malcangio M Miller M Tomlinson DR. A vitamin D3 derivative (CB1093) induces nerve growth factor and prevents neurotrophic deficits in streptozotocin-diabetic rats. Diabetologia 1999 42 : 1308 1313.
56. Anand P Terenghi G Warner G Kopelman PG Williams-Chestnut RE Sinicropi DV. The role of endogenous nerve growth factor in human diabetic neuropathy. Nat Med 1996 2 : 703 707.
57. Yiangou Y Facer P Sinicropi DV Boucher TJ Bennett DL McMahon SB et al. Molecular forms of NGF in human and rat neuropathic tissues: decreased NGF precursor-like immunoreactivity in human diabetic skin. J Peripher Nerv Syst 2002 7 : 190 197.
58. Muangman P Muffley LA Anthony JP Spenny ML Underwood RA Olerud JE et al. Nerve growth factor accelerates wound healing in diabetic mice. Wound Repair Regen 2004 12 : 44 52.
59. Terenghi G Mann D Kopelman PG Anand P. trkA and trkC expression is increased in human diabetic skin. Neurosci Lett 1997 228 : 33 36.
60. Werner S Breeden M Hubner G Greenhalgh DG Longaker MT. Induction of keratinocyte growth factor expression is reduced and delayed during wound healing in the genetically diabetic mouse. J Invest Dermatol 1994 103 : 469 473.
61. Brauchle M Angermeyer K Hubner G Werner S. Large induction of keratinocyte growth factor expression by serum growth factors and pro-inflammatory cytokines in cultured fibroblasts. Oncogene 1994 9 : 3199 3204.
62. Fahey TJ 3rd, Sadaty A Jones WG 2nd, Barber A Smoller B Shires GT. Diabetes impairs the late inflammatory response to wound healing. J Surg Res 1991 50 : 308 313.
63. Frank S Hübner G Breier G Longaker MT Greenhalgh DG Werner S. Regulation of vascular endothelial growth factor expression in cultured keratinocytes. J Biol Chem 1995 270 : 12607 12613.
64. Altavilla D Saitta A Cucinotta D Galeano M Deodato B Colonna M et al. Inhibition of lipid peroxidation restores impaired vascular endothelial growth factor expression and stimulates wound healing and angiogenesis in the genetically diabetic mouse. Diabetes 2001 50 : 667 674.
65. Di Peppe R Mangoni A Zambruno G Spinetti G Melillo G Napolitano M et al. Adenovirus-mediated VEGF(165) gene transfer enhances wound healing by promoting angiogenesis in CD1 diabetic mice. Gene Ther 2002 9 : 1271 1277.
66. Galeano M Deodato B Altavilla D Cucinotta D Arsic N Marini H et al. Adeno-associated viral vector-mediated human vascular endothelial growth factor gene transfer stimulates angiogenesis and wound healing in the genetically diabetic mouse. Diabetologia 2003 46 : 546 555.
67. Wetzler C Kampfer H Stallmeyer B Pfeilschifter J Frank S. Large and sustained induction of chemokines during impaired wound healing in the genetically diabetic mouse; prolonged persistence of neutrophils and macrophages during the late phase of repair. J Invest Dermatol 2000 115 : 245 253.
68. Dovi JV He LK DiPietro LA. Accelerated wound closure in neutrophil-depleted mice. J Leukoc Biol 2003 73 : 448 455.
69. Greenhalgh DG Sprugel KH Murray MJ Ross R. PDGF and FGF stimulate wound healing in the genetically diabetic mouse. Am J Pathol 1990 136 : 1235 1246.
70. Brown DL Kao WW-Y Greenhalgh DG. Apoptosis down-regulates inflammation under the advancing epithelial wound edge: delayed patterns in diabetes and improvement with topical growth factors. Surgery 1997 121 : 372 380.
71. Matsuda H Koyama H Sato H Sawada J Itakura A Tanaka A et al. Role of nerve growth factor in cutaneous wound healing: accelerating effects in normal and healing-impaired diabetic mice. J Exp Med 1998 187 : 297 306.
72. Canturk NZ Vural B Esen N Canturk Z Oktay G Kirkali G et al. Effects of granulocyte-macrophage colony-stimulating factor on incisional wound healing in an experimental diabetic rat model. Endocr Res 1999 25 : 105 116.
73. Ishikawa T Terai H Yamamoto T Harada K Kitajima T. Delivery of a growth factor fusion protein having collagen-binding activity to wound tissues. Artif Organs 2003 27 : 147 154.
74. Yoshida S Matsumoto K Tomioka D Bessho K Itami S Yoshikawa K et al. Recombinant hepatocyte growth factor accelerates cutaneous wound healing in a diabetic mouse model. Growth Factors 2004 22 : 111 119.
75. Wieman TJ The Becaplermin Gel Studies Group. Clinical efficacy of becaplermin (rhPDGF-BB) gel. Am J Surg 1998 176 : 74S 79S.
76. Bennett SP Griffiths GD Schor AM Leese GP Schor SL. Growth factors in the treatment of diabetic foot ulcers. Br J Surg 2003 90 : 133 146.
77. Tsang MW Wong WKR Hung CS Lai KM Tang W Cheung EYN et al. Human epidermal growth factor enhances healing of diabetic foot ulcers. Diabetes Care 2003 26 : 1856 1861.
78. Brown RL Breeden MP Greenhalgh DG. PDGF and TGF-α act synergistically to improve wound healing in the geneticaly diabetic mouse. J Surg Res 1994 56 : 562 570.
79. Edmonds M Bates M Doxford M Gough A Foster A. New treatments in ulcer healing and wound infection. Diabetes Metab Res Rev 2000 16 : S51 S54.
80. Harding KG Morris HL Patel GK. Healing chronic wounds. Br Med J 2002 324 : 160 163.
81. Sams HH Chen J King LE. Graftskin treatment of difficult to heal diabetic foot ulcers: one center's experience. Dermatol Surg 2002 28 : 698 703.
82. Lobmann R Pittasch D Muhlen I Lehnert H. Autologous human keratinocytes cultured on membranes composed of benzyl ester of hyaluronic acid for grafting in nonhealing diabetic foot lesions: a pilot study. J Diabetes Complications 2003 17 : 199 204.
83. Margolis DG Crombleholme T Herlyn M. Clinical protocol: phase I trial to evaluate the safety of H5.020CMV.PDGF-B for the treatment of a diabetic insensate foot ulcer. Wound Rep Regen 2000 8 : 480 493.
84. Scholzen T Armstrong CA Bunnett NW Luger TA Olerud JE Ansel JC. Neuropeptides in the skin: interactions between the neuroendocrine and the skin immune systems. Exp Dermatol 1998 7 : 81 96.
85. Ansel JC Kaynard AH Armstrong CA Olerud J Bunnett N Payan D. Skin-nervous system interactions. J Invest Dermatol 1996 106 : 198 204.
86. Lindsay RM Harmar AJ. Nerve growth factor regulates expression of neuropeptide genes in adult sensory neurons. Nature 1989 337 : 362 364.
87. Lindsay RM Lockett C Sternberg J Winter J. Neuropeptide expression of adult sensory neurons: modulation of substance P and calcitonin gene-regulated peptide levels by nerve growth factor. Neuroscience 1989 33 : 53 65.
88. Kennedy WR Wendelschafer-Crabb G Johnson T. Quantitation of epidermal nerves in diabetic neuropathy. Neurology 1996 47 : 1042 1048.
89. Gibran NS Jang YC Isik FF Greenhalgh DG Muffley LA Underwood RA et al. Diminished neuropeptide levels contribute to impaired cutaneous healing response associated with diabetes mellitus. J Surg Res 2002 108 : 122 128.
90. Levy DM Terenghi G Gu XH Abraham RR Springall DR Polak JM. Immunohistochemical measurements of nerves and neuropeptides in diabetic skin: relationship to tests of neurological function. Diabetologia 1992 35 : 889 897.
91. Levy DM Karanth SS Springall DR Polak JM. Depletion of cutaneous nerves and neuropeptides in diabetes mellitus: an immunocytochemical study. Diabetologia 1989 32 : 427 433.
92. Muangman P Spenny ML Tamura RN Gibran NS. Fatty acids and glucose increase neutral endopeptidase activity in human microvascular endothelial cells. Shock 2003 19 : 508 512.
93. Antezana MA Sullivan SR Usui ML Gibran NS Spenny ML Larsen JA et al. Neutral endopeptidase activity is increased in the skin of subjects with diabetic ulcers. J Invest Dermatol 2002 119 : 1400 1404.
94. Spenny ML Muangman P Sullivan SR Bunnett NW Ansel JC Olerud JE et al. Neutral endopeptidase inhibition in diabetic wound repair. Wound Rep Regen 2002 10 : 295 301.
95. Radomski MW. Nitric oxide: biological mediator, modulator and effector. Ann Med 1995 27 : 321 329.
96. Appleton I Tomlinson A Willoughby DA. Induction of cyclo-oxygenase and nitric oxide synthase in inflammation. Adv Pharmacol 1996 35 : 27 78.
97. Bruch-Gerharz D Ruzicka T Kolb-Bachofen V. Nitric oxide in human skin: current status and future prospects. J Invest Dermatol 1998 110 : 1 7.
98. Reichner JS Meszaros AJ Louis CA Henry WL Jr, Mastrofrancesco B Martin BA et al. Molecular and metabolic evidence for the restricted expression of inducible nitric oxide synthase in healing wounds. Am J Pathol 1999 154 : 1097 1104.
99. Lee RH Efron D Tantry U Barbul A. Nitric oxide in the healing wound: a time-course study. J Surg Res 2001 101 : 104 108.
100. Moilanen E Vapaatalo H. Nitric oxide in inflammation and immune response. Ann Med 1995 27 : 359 367.
101. Papapetropoulos A Desai KM Rudic RD Mayer B Zhang R Ruiz-Torres MP et al. Nitric oxide synthase inhibitors attenuate transforming-growth-factor-β1- stimulated capillary organization in vitro. Am J Pathol 1997 150 : 1835 1844.
102. Babaei S Teichert-Kuliszewska K Monge JC Mohamed F Bendeck MP Stewart DJ. Role of nitric oxide in the angiogenic response in vitro to basic fibroblast growth factor. Circ Res 1998 82 : 1007 1015.
103. Yamasaki K Edington HD McClosky C Tzeng E Lizonova A Kovesdi I et al. Reversal of impaired wound repair in iNOS-deficient mice by topical adenoviral-mediated iNOS gene transfer. J Clin Invest 1998 101 : 967 971.
104. Thornton FJ Schaffer MR Witte MB Moldawer LL MacKay SL Abouhamze A et al. Enhanced collagen accumulation following direct transfection of the inducible nitric oxide synthase gene in cutaneous wounds. Biochem Biophys Res Commun 1998 246 : 654 659.
105. Lee PC Salyapongse AN Bragdon GA Shears LL 2nd, Watkins SC Edington HD et al. Impaired wound healing and angiogenesis in eNOS-deficient mice. Am J Physiol 1999 277 : H1600 1608.
106. Stallmeyer B Kampfer H Kolb N Pfeilschifter J Frank S. The function of nitric oxide in wound repair: inhibition of inducible nitric oxide-synthase severely impairs wound re-epithelialization. J Invest Dermatol 1999 113 : 1090 1098.
107. Shi HP Efron DT Most D Barbul A. The role of iNOS in wound healing. Surgery 2001 130 : 225 229.
108. Schaffer MR Tantry U Efron PA Ahrendt GM Thornton FJ Barbul A. Diabetes-impaired healing and reduced wound nitric oxide synthesis: a possible pathophysiologic correlation. Surgery 1997 121 : 513 519.
109. Witte MB Thornton FJ Tantry U Barbul A. l-Arginine supplementation enhances diabetic wound healing: involvement of nitric oxide synthase and arginase pathways. Metabolism 2002 51 : 1269 1273.
110. Kampfer H Pfeilschifter J Frank S. Expression and activity of arginase isoenzymes during normal and diabetes-impaired skin repair. J Invest Dermatol 2003 121 : 1544 1551.
111. Stallmeyer B Anhold M Wetzler C Kahlina K Pfeilschifter J Frank S. Regulation of eNOS in normal and diabetes-impaired skin repair: implications for tissue regeneration. Nitric Oxide 2002 6 : 168 177.
112. Albina JE Mills CD Henry WL Caldwell MD. Temporal expression of different pathways of l-arginine metabolism in healing wounds. J Immunol 1990 144 : 3880.
113. Chang CI Liao JC Kuo L. Arginase modulates nitric oxide production in activated macrophages. Am J Physiol 1998 274 : H342 348.
114. Mayer B John M Heinzel B Werner ER Wachter H Schultz G et al. Brain nitric oxide synthase is a biopterin- and flavin-containing multi-functional oxido-reductase. FEBS Lett 1991 288 : 187 191.
115. Culcasi M Lafon-Cazal M Pietri S Bockaert J. Glutamate receptors induce a burst of superoxide via activation of nitric oxide synthase in arginine-depleted neurons. J Biol Chem 1994 269 : 12589 12593.
116. Beckman JS Beckman TW Chen J Marshall PA Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990 87 : 1620 1624.
117. Radi R Beckman JS Bush KM Freeman BA. Peroxynitrite oxidation of sulfhydryls. The cytotoxic potential of superoxide and nitric oxide. J Biol Chem 1991 266 : 4244 4250.
118. Douki T Cadet J. Peroxynitrite-mediated oxidation of purine bases of nucleosides and isolated DNA. Free Rad Res 1996 24 : 369 380.
119. Szabo C. DNA strand breakage and activation of poly-ADP ribosyltransferase: a cytotoxic pathway triggered by peroxynitrite. Free Rad Biol Med 1996 21 : 855 869.
120. Arana V Paz Y Gonzalez A Mendez V Mendez JD. Healing of diabetic foot ulcers in l-arginine-treated patients. Biomed Pharmacother 2004 58 : 588 597.
121. Shi HP Most D Efron DT Witte MB Barbul A. Supplement l-arginine enhances wound healing in diabetic rats. Wound Rep Regen 2003 11 : 198 203.
122. Jude EB Tentolouris N Appleton I Anderson S Boulton AJM. Role of neuropathy and plasma nitric oxide in recurrent neuropathic and neuroischemic diabetic foot ulcers. Wound Rep Regen 2001 9 : 353 359.
123. Abd-El-Aleem SA Ferguson MW Appleton I Kairsingh S Jude EB Jones K et al. Expression of nitric oxide synthase isoforms and arginase in normal human skin and chronic venous leg ulcers. J Pathol 2000 191 : 434 442.
124. Vodovotz Y Bogdan C Paik J Xie QW Nathan C. Mechanisms of suppression of macrophage nitric oxide release by transforming growth factor β. J Exp Med 1993 178 : 605 613.
125. Vodovotz Y Letterio JJ Geiser AG Chesler L Roberts AB Sparrow J. Control of nitric oxide production by endogenous TGF-β1 and systemic nitric oxide in retinal pigment epithelial cells and peritoneal macrophages. J Leukoc Biol 1996 60 : 261 270.
126. Peng HB Spiecker M Liao JK. Inducible nitric oxide: an autoregulatory feedback inhibitor of vascular inflammation. J Immunol 1998 161 : 1970 1976.
127. Pipili-Synetos E Sakkoula E Haralabopoulos G Andriopoulou P Peristeris P Maragoudakis ME. Evidence that nitric oxide is an endogenous antiangiogenic mediator. Br J Pharmacol 1994 111 : 894 902.
128. Lloyd-Jones DM Bloch KD. The vascular biology of nitric oxide and its role in atherogenesis. Annu Rev Med 1996 47 : 365 375.
129. Johnson LL Dyer R Hupe DJ. Matrix metalloproteinases. Curr Opin Chem Biol 1998 2 : 466 471.
130. Armstrong DG Jude EB. The role of matrix metalloproteinases in wound healing. J Am Podiatr Med Assoc 2002 92 : 12 18.
131. Fischer C Gilbertson-Beadling S Powers EA Petzold G Poorman R Mitchell MA. Interstitial collagenase is required for angiogenesis in vitro. Dev Biol 1994 162 : 499 510.
132. Madlener M Parks WC Werner S. Matrix metalloproteinases (MMPs) and their physiological inhibitors (TIMPs) are differentially expressed during excisional skin wound repair. Exp Cell Res 1998 242 : 201 210.
133. Leppert D Lindberg RL Kappos L Leib SL. Matrix metalloproteinases: multifunctional effectors or inflammation in multiple sclerosis and bacterial meningitis. Brain Res Brain Res Rev 2001 36 : 249 257.
134. D'Armiento J. Matrix metalloproteinase disruption of the extracellular matrix and cardiac dysfunction. Trends Cardiovasc Med 2002 12 : 97 101.
135. Nwomeh BC Liang HX Cohen IK Yager DR. MMP-8 is the predominant collagenase in healing wounds and non-healing ulcers. J Surg Res 1999 81 : 189 195.
136. Trengrove NJ Stacey MC Macauley S Bennett N Gibson J Burslem F et al. Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors. Wound Rep Regen 1999 7 : 442 452.
137. Rechardt O Elomaa O Vaalamo M Paakkonen K Jahkola T Hook-Nikanne J et al. Stromelysin-2 is upregulated during normal wound repair and is induced by cytokines. J Invest Dermatol 2000 115 : 778 787.
138. Lobmann R Ambrosch A Schultz G Waldmann K Schiweck S Lehnert H. Expression of matrix-metalloproteinases and their inhibitors in the wounds of diabetic and non-diabetic patients. Diabetologia 2002 45 : 1011 1016.
139. Neely AN Clendening CE Gardner J Greenhalgh DG. Gelatinase activities in wounds of healing-impaired mice versus wounds of non-healing-impaired mice. J Burn Care Rehabil 2000 21 : 395 402.
140. Nagase H. Stromelysins 1 and 2. In : Parks WC Mecham RP, eds. Matrix Metalloproteinases. San Diego : Academic Press 1998 : 43 84.
141. Nakamura H Fujii Y Ohuchi E Yamamoto E Okada Y. Activation of the precursor of human stromelysin 2 and its interactions with other matrix metalloproteinases. Eur J Biochem 1998 253 : 67 75.
142. Ito A Sato T Iga T Mori Y. Tumor necrosis factor bifunctionally regulates matrix metalloproteinases and tissue inhibitor of metalloproteinases (TIMP) production by human fibroblasts. FEBS Lett 1990 269 : 93 95.
143. Wall SJ Sampson MJ Levell N Murphy G. Elevated matrix metalloproteinase-2 and -3 production from human dermal fibroblasts. Br J Dermatol 2003 149 : 13 16.
144. Edwards DR Murhy G Reynolds JJ Whitham SE Dochery AJP Angel P et al. Transforming growth factor β modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J 1987 6 : 1899 1904.
145. Kerr LD Miller DB Matrisian LM. TGF-β1 inhibition of transin/stromelysin gene expression is mediated through a Fos binding sequence. Cell 1990 61 : 267 278.
146. Bertaux B Hornebeck W Eisen AZ Dubertret L. Growth stimulation of human keratinocytes by tissue inhibitor of metalloproteinases. J Invest Dermatol 1991 97 : 679 685.
147. Hayakawa T Yamashita K Tanzawa K Uchijima E Iwata K. Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. FEBS Lett 1992 298 : 29 32.
148. Hayakawa T Yamashita K Ohuchi E Shinagawa A. Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). J Cell Sci 1994 107 : 2373 2379.
149. Cullen B Smith R McCulloch E Silcock D Morrison L. Mechanism of action of action of PROMOGRAN, a protease modulating matrix, for the treatment of diabetic foot ulcers. Wound Repair Regen 2002 10 : 16 25.
150. Ghatnekar O Willis M Persson U. Cost-effectiveness of treating deep diabetic foot ulcers with Promogran in four European countries. J Wound Care 2002 11 : 70 74.
151. Terasaki K Kanzaki T Aoki T Iwata K Saiki I. Effects of recombinant human tissue inhibitor of metalloproteinases-2 (rh-TIMP-2) on the migration of epidermal keratinocytes in vitro and wound healing in vivo. J Dermatol 2003 30 : 165 172.
152. Loots MAM Lamme EN Zeegelaar J Mekkes JR Bos JD Middelkoop E. Differences in cellular infiltrate and extracellular matrix of chronic diabetic and venous ulcers versus acute wounds. J Invest Dermatol 1998 111 : 850 857.
153. Wierusz-Wysocka B Wysocki H Wykretowicz A Szczepanik A Siekierka H. Phagocytosis, bactericidal capacity, and superoxide anion (02-) production by polymorphonuclear neutrophils from patients with diabetes mellitus. Folia Haematol Int Mag Klin Morph Blutforsch 1985 112 : 658 668.
154. Rayfield EJ Ault MJ Keusch GT Brothers MJ Nechemias C Smith H. Infection and diabetes: the case for glucose control. Am J Med 1982 72 : 439 450.
155. Waltenberger J Lange J Kranz A. Vascular endothelial growth factor-A-induced chemotaxis of monocytes is attenuated in patients with diabetes mellitus. Circulation 2000 102 : 185 190.
156. Loots MAM Lamme EN Mekkes JR Bos JD Middelkoop E. Cultured fibroblasts from chronic diabetic wounds on the lower extremity (non-insulin-dependent diabetes mellitus) show disturbed proliferation. Arch Dermatol Res 1999 291 : 93 99.
157. Hehenberger K Kratz G Hansson A Brismar K. Fibroblasts derived from human chronic diabetic wounds have a decreased proliferation rate, which is recovered by the addition of heparin. J Dermatol Sci 1998 16 : 144 151.
158. Loots MAM Kenter SB Au FL van Galen WJM Middelkoop E Bos JD et al. Fibroblasts derived from chronic diabetic ulcers differ in their response to stimulation with EGF, IGF-I, bFGF and PDGF-AB compared to controls. Eur J Cell Biol 2002 81 : 153 160.
159. Seibold JR Uitto J Dorwart BB Prockop DJ. Collagen synthesis and collagenase activity in dermal fibroblasts from patients with diabetes and digital sclerosis. J Lab Clin Med 1985 105 : 664 667.
160. Kilanczyk E Bryszewska M. The effect of melatonin on antioxidant enzymes in human diabetic skin fibroblasts. Cell Mol Biol Lett 2003 8 : 333 336.
161. Lerman OZ Galiano RD Armour M Levine JP Gurtner GC. Cellular dysfunction in the diabetic fibroblast. Am J Pathol 2003 162 : 303 312.
162. Nass SL Li M Amundadottir LT Furth PA Dickson RB. Role for Bcl-xL in the regulation of apoptosis by EGF and TGFβ1 in c-myc overexpressing mammary epithelial cells. Biochem Biophys Res Commun 1996 227 : 248 256.
163. Sillett HK Cruickshank SM Southgate J Trejdosiewicz LK. Transforming growth factor-β promotes 'death by neglect' in post-activated human T cells. Immunology 2001 102 : 310 316.
164. Yasuda K Aoshiba K Nagai A. Transforming growth factor-β promotes fibroblast apoptosis induced by H2O2. Exp Lung Res 2003 29 : 123 134.
165. Maritim AC Sanders RA Watkins JB 3rd. Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol 2003 17 : 24 38.
166. Thorpe SR Baynes JW. Maillard reaction products in tissue proteins: new products and new perspectives. Amino Acids 2003 25 : 275 281.
167. Bonnefont-Rousselot D. Glucose and reactive oxygen species. C urr Opin Clin Nutr Metab Care 2002 5 : 561 568.
168. Mudge BP Harris C Gilmont RR Adamson BS Rees RS. Role of glutathione redox dysfunction in diabetic wounds. Wound Repair Regen 2002 10 : 52 58.
169. Rasik AM Shukla A. Antioxidant status in delayed healing type of wounds. Int J Exp Pathol 2000 81 : 257 263.
170. Muruganandam A Drouillard C Thibert RJ Cheung RM Draisey TF Mutus B. Glutathione metabolic enzyme activities in diabetic platelets as a function of glycemic control. Throm Res 1992 67 : 385 397.
171. Muchova J Liptakova A Orszaghova Z Garaiova I Tison P Carsky J et al. Antioxidant systems in polymorphonuclear leucocytes of type 2 diabetes mellitus. Diabet Med 1999 16 : 74 78.
172. Halliwell B Aruoma OI. DNA damage by oxygen-derived species. Its mechanism and measurement in mammalian systems. FEBS Lett 1991 281 : 9 19.
173. Dandona P Thusu K Cook S Snyder B Makowski J Armstrong D et al. Oxidative damage to DNA in diabetes mellitus. Lancet 1996 347 : 444 445.
174. Dincer Y Akcay T Ilkova H Alademir Z Ozbay G. DNA damage and antioxidant defense in peripheral leukocytes of patients with type I diabetes mellitus. Mutat Res 2003 527 : 49 55.
175. Hannon-Fletcher MPA O'Kane M Moles KW Weatherup C Barnett CR Barnett YA. Levels of peripheral blood cell DNA damage in insulin dependent diabetes mellitus human subjects. Mutat Res 2000 460 : 53 60.
176. Sampson MJ Astley S Richardson T Willis G Davies IR Hughes DA et al. Increased DNA oxidative susceptibility without increased plasma LDL oxidizability in type II diabetes: effects of α-tocopherol supplementation. Clin Sci 2001 101 : 235 241.
177. Arnold F West DC. Angiogenesis in wound healing. Pharmacol Ther 1991 52 : 407 422.
178. Martin A Komada MR Sane DC. Abnormal angiogenesis in diabetes mellitus. Med Res Rev 2003 23 : 117 145.
179. Brem H Jacobs T Vileikyte L Weinberger S Gibber M Gill K et al. Wound-healing protocols for diabetic foot and pressure ulcers. Surg Technol Int 2003 11 : 85 92.
180. Teixeira AS Andrade SP. Glucose-induced inhibition of angiogenesis in the rat sponge granuloma is prevented by aminoguanidine. Life Sci 1999 64 : 655 662.
181. Griffioen AW Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular disease and chronic inflammation. Pharmacol Rev 2000 52 : 237 268.
182. Okumura M Okuda T Nakamura T Yajima M. Acceleration of wound healing in diabetic mice by basic fibroblast growth factor. Biol Pharm Bull 1996 19 : 530 535.
183. Cechowska-Pasko M Palka J Bankowski E. Decrease in the glycosaminoglycan content in the skin of diabetic rats. The role of IGF-I, IGF-binding proteins and proteolytic activity. Mol Cell Biochem 1996 154 : 1 8.
184. Galeano M Torre V Deodato B Campo GM Colonna M Sturiale A et al. Raxofelast, a hydrophilic vitamin E-like antioxidant, stimulates wound healing in genetically diabetic mice. Surgery 2001 129 : 467 477.
185. Bertheim U Engstrom-Laurent A Hofer PA Hallgren P Asplund J Hellstrom S. Loss of hyaluronan in the basement membrane zone of the skin correlates to the degree of stiff hands in diabetic patients. Acta Derm Venereol 2002 82 : 329 334.
186. Craig RG Yu Z Xu L Barr R Ramamurthy N Boland J Schneir M et al. A chemically modified tetracycline inhibits streptozotocin-induced diabetic depression of skin collagen synthesis and steady-state type I procollagen mRNA. Biochim Biophys Acta 1998 1402 : 250 260.
187. Deckert T Horowitz IM Kofoed-Enevoldsen A Kjellen L Deckert M Lykkelund C et al. Possible genetic defects in regulation of glycosaminoglycans in patients with diabetic nephropathy. Diabetes 1991 40 : 746 770.
188. Cechowska-Pasko M Palka J Bankowski E. Decreased biosynthesis of glycosaminoglycans in the skin of rats with chronic diabetes mellitus. Exp Toxicol Pathol 1999 51 : 239 243.
189. Black E Vibe-Petersen J Jorgensen LN Madsen SM Agren MS Holstein PE et al. Decrease of collagen deposition in wound repair in type 1 diabetes independent of glycemic control. Arch Surg 2003 138 : 34 40.
190. Goodson WH 3rd, Hunt TK. Wound collagen accumulation in obese hyperglycemic mice. Diabetes 1986 35 : 491 495.
191. Witte MB Kiyama T Barbul A. Nitric oxide enhances experimental wound healing in diabetes. Br J Surg 2002 89 : 1594 1601.
192. Masters KSB Leibovich SJ Belem P West JL Poole-Warren LA. Effects of nitric oxide releasing poly (vinyl alcohol) hydrogel dressings on dermal wound healing in diabetic mice. Wound Repair Regen 2002 10 : 286 292.
193. Telasky C Tredget EE Shen Q Khorramizadeh MR Iwashina T Scott PG et al. IFN-αb suppresses the fibrogenic effects of insulin-like growth factor-1 in dermal fibroblasts. J Interferon Cytokine Res 1998 18 : 571 577.
194. Reed MJ Vernon RB Abrass IB Sage EH. TGF-β1 induces the expression of type I collagen and SPARC, and enhances contraction of collagen gels, by fibroblasts from young and aged donors. J Cell Physiol 1994 158 : 169 179.
195. Kuroda K Utani A Hamasaki Y Shinkai H. Up-regulation of putative hyaluronan synthase mRNA by basic fibroblast growth factor and insulin-like growth factor-1 in human skin fibroblasts. J Dermatol Sci 2001 26 : 156 160.
196. Beswick HT Harding JJ. Conformational changes induced in lens α- and γ-crystallins by modification with glucose 6-phosphate. Implications for cataract. Biochem J 1987 246 : 761 769.
197. Lutjens A Jonkhoff-Slok TW Sandkuijl C vd Veen EA vd Meer J. Polymerisation and crosslinking of fibrin monomers in diabetes mellitus. Diabetologia 1988 31 : 825 830.
198. Yan H Harding JJ. Inactivation and loss of antigenicity of esterase by sugars and a steroid. Biochem Biophys Acta 1999 1454 : 183 190.
199. Ahmed N. Advanced glycation endproducts - role in pathology of diabetic complications. Diabetes Res Clin Pract 2005 67 : 3 21.
200. Pomposelli JJ Baxter JK 3rd, Babineau TJ Pomfret EA Driscoll DF Forse RA et al. Early post-operative glucose control predicts nosocomial infection rate in diabetic patients. J Parenter Enteral Nutr 1998 22 : 77 81.
201. Charlesworth JA Timmermans V Golding J Campbell LV Peake PW Pussel BA et al. The complement system in type 1 (insulin-dependent) diabetes. Diabetologia 1987 30 : 372 379.
202. Hehenberger K Hansson A. High glucose-induced growth factor resistance in human fibroblasts can be reversed by antioxidants and protein kinase C-inhibitors. Cell Biochem Funct 1997 15 : 197 201.
203. Duraisamy Y Gaffney J Slevin M Smith CA Williamson K Ahmed N. Aminosalicylic acid reduces the antiproliferative effect of hyperglycaemia, advanced glycation endproducts and glycated basic fibroblast growth factor in cultured bovine aortic endothelial cells: comparison with aminoguanidine. Mol Cell Biochem 2003 246 : 143 153.
204. Spravchikov N Sizyakov G Gartsbein M Accili D Tennenbaum T Wertheimer E. Glucose effects on skin keratinocytes: implications for diabetes skin complications. Diabetes 2001 50 : 1627 1635.
205. Death AK Fisher EJ McGrath KCY Yue DK. High glucose alters matrix metalloproteinase expression in two key vascular cells: potential impact on atherosclerosis in diabetes. Atherosclerosis 2003 168 : 263 269.
206. Uemura S Matsushita H Li W Glassford AJ Asagami T Lee KH et al. Diabetes mellitus enhances vascular matrix metalloproteinase activity. Circ Res 2001 88 : 1291 1298.
207. Tsilibary EC Charonis AS Reger LA Wohlhueter RM Furcht LT. The effect of nonenzymatic glucosylation on the binding of the main non-collagenous NC1 domain to type IV collagen. J Biol Chem 1988 263 : 4302 4308.
208. Charonis AS Reger LA Dege JE Kouzi-Koliakos K Furcht LT Wohlhueter RM et al. Laminin alterations after in vitro non-enzymatic glycoslylation. Diabetes 1990 39 : 807 814.
209. Brownlee M Vlassara H Cerami A. Non-enzymatic glycosylation reduces the susceptibility of fibrin to degradation by plasmin. Diabetes 1983 32 : 680 684.
210. Mott JD Khalifah RG Nagase H Shield CF 3rd, Hudson JK Hudson BG. Non-enzymatic glycation of type IV collagen and matrix metalloproteinase susceptibility. Kidney Int 1997 52 : 1302 1312.
211. Kawano E Takahashi S Sakano Y Fujimoto D. Non-enzymatic glycation alters properties of collagen as a substratum for cells. Matrix 1990 10 : 300 305.
212. Hasegawa G Hunter AJ Charonis AS. Matrix non-enzymatic glycosylation leads to altered cellular phenotype and intracellular tyrosine phosphorylation. J Biol Chem 1995 270 : 3278 3283.
213. Rittie L Berton A Monboisse JC Hornebeck W Gillery P. Decreased contraction of glycated collagen lattices coincides with impaired matrix metalloproteinase production. Biochem Biophys Res Commun 1999 264 : 488 492.
214. Schnider SL Kohn RR. Effects of age and diabetes mellitus on the solubility and non-enzymatic glucosylation of human skin collagen. J Clin Invest 1981 67 : 1630 1635.
215. Reihsner R Melling M Pfeiler W Menzel EJ. Alterations of biochemical and two-dimensional biomechanical properties of human skin in diabetes mellitus as compared to effects of in vitro non-enzymatic glycation. Clin Biomech 2000 15 : 379 386.
216. Andreassen TT Seyer-Hansen K Oxlund H. Biomechanical changes in connective tissues induced by experimental diabetes. Acta Endocrinol 1981 98 : 432 436.
217. Yang S Litchfield JE Baynes JW. AGE-breakers cleave model compounds, but do not break Maillard crosslinks in skin and tail collagen from diabetic rats. Arch Biochem Biophys 2003 412 : 42 46.
218. Kawamura N Ookawara T Suzuki K Konishi K Mino M Taniguchi N. Increased glycated Cu, Zn-superoxide dismutase levels in erythrocytes of patients with insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1992 74 : 1352 1354.
219. Williams DRR. The size of the problem; epidemiological and economic aspects of foot problems in diabetes mellitus. In : Boulton AJM Connor H Cavanagh PR, eds. The Foot in Diabetes, 2nd edn. Chichester : John Wiley and Sons 1994, 15 24.
220. Harrington C Zagari MJ Corea J Klitenic J. A cost analysis of diabetic lower- extremity ulcers. Diabetes Care 2000 23 : 1333 1338.
221. King H Aubert RE Herman WH. Global burden of diabetes, 1995-2025. Diabetes Care 1998 21 : 1414 1431.